Taken together, we envision that a blood panel will eventually become available for patients, in which astrogliosis can be assessed by measuring the levels of GFAP, innate immune inflammation can be assessed with the blood levels of ASC and IL-1β, microglia status can be assessed with TREM2, neuronal status can be assessed with neurofilament light (NfL) and pTau217, and amyloidosis can be assessed with amyloid-β (Aβ42:40) levels. The gene discussed is NEFL; the disease is amyloidosis.